Prostamax

Prostamax is a synthetic tetrapeptide composed of lysine, glutamic acid, aspartic acid, and proline (Lys-Glu-Asp-Pro, single-letter code KEDP). It belongs to the Khavinson Cytogen class developed at the St. Petersburg Institute of Bioregulation and Gerontology and is marketed as the prostate-targeting Cytogen, sometimes paired with a corresponding prostate Cytomax in extended Russian protocols.

The Khavinson bioregulator program produced two parallel compound classes. Cytomaxes are organ-specific peptide extracts from young animal tissues containing heterogeneous mixtures of peptides up to several kDa. Cytogens are short synthetic peptides, typically two to four amino acids, designed to reproduce a single defined active sequence identified within the corresponding Cytomax. For the prostate, Prostamax is the synthetic Cytogen with the KEDP sequence. The shorter Vesilute dipeptide (Glu-Asp, ED) is positioned as the bladder Cytogen and shares the central ED residues with Prostamax.

The compound is described across Khavinson group publications on peptide-DNA interaction and tissue-specific gene-expression regulation. The 2021 systematic review by Khavinson and colleagues summarizes the broader framework. Independent confirmation of the prostate-tissue specificity claim by Western groups is sparse.

The Human Evidence

The compound-specific clinical evidence base consists of:

• Russian-institution clinical observation studies in elderly men with benign prostatic hyperplasia
• Reports of use in chronic prostatitis treatment protocols
• Inclusion in geroprotective protocols by Russian and former-Soviet medical institutions
• Manufacturer documentation describing improvement in IPSS scores after 30-day courses

Independent Western replication is absent. PubMed indexing returns Khavinson-affiliated publications. No registered ClinicalTrials.gov study exists for Prostamax as of May 2026. The published efficacy claims rest on open-label observational reports rather than blinded randomized trials.

The Khavinson group's body of work on peptide bioregulation has produced peer-reviewed mechanistic papers across multiple Cytogens and has built a coherent theoretical framework. The compound-specific clinical data for Prostamax, however, sits inside the same institutional network that developed it. Both should be understood honestly when evaluating the compound.

Regulatory and Legal Status

FDA. No approval. Not on bulk drug substances list. Importation permitted only as a research chemical labeled "not for human consumption."

EMA. No approval.

Russia. Registered as a biologically active dietary supplement. Sold in oral capsule format through the Khavinson distribution network.

WADA. Not on the 2026 Prohibited List.

The proposed mechanism follows the Khavinson short-peptide bioregulation model with prostate-tissue specificity.

Cellular entry. KEDP is hypothesized to enter prostate epithelial and stromal cells through peptide transporters (PEPT1, PEPT2), reach the nucleus, and modulate transcription.

DNA-binding selectivity. The Khavinson group reports that short peptides bind selectively to AT-rich promoter regions of tissue-specific genes. For Prostamax, the proposed target gene clusters include genes governing prostate epithelial cell proliferation, fluid secretion, smooth muscle tone, and inflammatory signaling pathways.

Downstream effects. Khavinson group publications report Prostamax effects in prostate tissue culture models including modulation of cell proliferation, reduction in inflammatory cytokine markers, and improvement in markers of glandular function. The 5-alpha-reductase / dihydrotestosterone pathway is not directly targeted; the mechanism is positioned as upstream of androgen signaling and complementary rather than competing with pharmaceutical BPH agents like finasteride.

Pharmacokinetics. Oral tetrapeptides face gut hydrolysis to free amino acids. The Khavinson group has addressed this with two arguments: partial PEPT1-mediated absorption of intact tetrapeptide, and signaling initiated at the gut-mucosa interface and propagated systemically through neural and humoral pathways. Direct measurement of intact Prostamax in plasma after oral administration has not been published.

Human pharmacokinetic data is not published in any peer-reviewed journal indexed in major Western databases.

Reported effects come from Russian-institution clinical observation studies and from research-chemical user reports.

Russian-institution reports describe:

• Reduction in IPSS (International Prostate Symptom Score) in elderly men with BPH
• Improvement in nocturia frequency
• Reduction in subjective symptoms of chronic prostatitis
• Possible reduction in post-void residual urine volume in BPH patients
• Adjunct effects in protocols for radiation-induced or post-surgical prostate inflammation

Research-chemical user reports include subjective improvement in urinary stream, reduced nocturia, and perceived improvement in prostate-related symptoms after multiple weeks of capsule use. These reports are anecdotal, uncontrolled for placebo, and not verified for vial identity in research-chemical settings.

None of these effects has been quantified in a placebo-controlled trial published in an English-language indexed journal.

No standardized human dosing protocol supported by independent pharmacokinetic data exists for Prostamax.

The Russian retail product is dosed as 1 to 2 capsules once or twice daily before meals for a 30-day course, repeated 2 to 3 times per year per manufacturer recommendation. Each capsule contains approximately 20 mg of active peptide. After the Cytogen course, the Khavinson protocol typically transitions to the corresponding Cytomax for extended support.

Research-chemical Prostamax is sold as lyophilized powder in 20 mg vials. Subcutaneous dosing protocols in research-chemical communities use 200 to 500 mcg daily over 10 to 20 day cycles, with multiple cycles per year. These protocols are extrapolated from generic Khavinson recommendations and lack Prostamax-specific human pharmacokinetic support.

The Khavinson bioregulator class has a benign published adverse-event profile. The Russian manufacturer documentation for Prostamax lists individual intolerance to components, pregnancy, and lactation as contraindications. No serious adverse events are reported in the Russian-language clinical literature.

The constituent amino acids (lysine, glutamic acid, aspartic acid, proline) are common dietary amino acids. Tetrapeptide doses at the microgram-to-milligram level fall within typical dietary peptide exposure. Acute toxicity is mechanistically unlikely.

The relevant safety question is chronic effects on prostate gene expression. Long-term human safety data with controlled endpoints does not exist. A theoretical concern raised in Western reviews is that any compound claimed to modulate prostate epithelial cell proliferation could in principle have unpredictable effects in patients with subclinical or undiagnosed prostate malignancy. This concern has not been formally evaluated in long-term safety studies with prostate-cancer-specific endpoints.

Drug-drug interaction data with 5-alpha-reductase inhibitors, alpha-1 blockers, or PDE-5 inhibitors is absent.

Within the Khavinson system, Prostamax is the initial-phase Cytogen for prostate bioregulation, usually followed by the corresponding Cytomax in standard protocols. For broader urogenital coverage, Prostamax is paired with Vesilute (bladder Cytogen) and Vesugen (vascular Cytogen for genitourinary microcirculation support).

For testicular-axis stacks, Prostamax is combined with Testagen (testicular Cytogen) and Testoluten (testicular Cytomax). For broader geroprotective protocols, it joins Epitalon (pineal) and other organ-specific Cytogens. No combined-stack human trial has been published.

External pharmaceutical comparators for BPH are 5-alpha-reductase inhibitors (finasteride, dutasteride) and alpha-1 adrenergic blockers (tamsulosin, alfuzosin). These have Phase 3 trial evidence for symptom improvement and disease modification. Prostamax has no comparable evidence base and is not a substitute for any of these medications in clinically significant BPH or in suspected prostate malignancy.

For informational and educational purposes only. Not medical advice. Not for human consumption unless prescribed by a licensed physician for an FDA-approved indication. Consult a qualified healthcare provider before using any peptide or pharmaceutical product.